Hot news. MWIS Are Hot.

EXPLOSIVE PICK FOR OUR MEMBERS
RIDE THE STAIRWAY TO HEAVEN!

Date: 30 Sep 2005
Company Name: m-Wise
Stock Name: MWIS
Price: $0.155
Short Term Target: $0.5 - 0.6
12month Target: $1 (!!!)

***
About m-Wise

Founded in February 2000, m-Wise has rapidly established itself
as a leading technology provider with the de facto
Service Delivery Platform and related value-added data engines
for Mobile Operators, Wireless ASPs, and large content
and media providers.

Working closely with leading operators, ASPs and content providers,
m-Wise is committed to take the lead and keep up to date
with the latest industry headways in areas as diverse
as content management and delivery, infotainment, mobile gaming
and mobile community services.
***

This stock will explode. Do not wait until it is too late!

Micro-Cap stocks Are About Timing

WE TOLD YOU TO WATCH.
IT'S STILL NOT TOO LATE...
TRADING ALERT!
Timing is everything!!!

Date: 27 Sep 2005
Company: China World Trade Corporation
Symbol: CWTD.OB
Price: $1.91
7-Day Target: $3-4
3-Month Target: $8-9
Status: Strong Buy
Rating: 5(5)

---
About China World Trade Corporation

China World Trade Corporation (CWTC) has established its business
in three distinct areas: the club and business centers throughout
major cities in China, business travel-related services,
and business value-added services. The Club and Business Center Division
is devoted to the building of the World Trade brand throughout China
via the opening and operating of business clubs in China's major,
positioning the CWTC to act as a platform to facilitate trade
between China and the world markets. The acquisition
of CEO Clubs China Limited ("CEO Clubs") in May 2004 further complements
CWTC's offerings by targeting high-level corporate executives
from premier companies. The Business Traveling Services Division,
New Generation, provides CWTC access to the rapidly growing
travel-related industry. New Generation is a pioneer
and market leader in the travel agency business through
its strong network of ticketing sales operations throughout Southern China.
The Business Value-Added Services Division focuses on value-added services
of credit cards, merchant-related business services, as well
as consultancy services to CWTC members and clients.
Guangdong World Trade Link Information Services Limited ("WTC Link"),
a subsidiary of CWTC, manages the Company's co-branded credit card project
and is an active provider of CRM solutions and services in China.
---

WATCH OUT! STOCK is ready to ROCK !!!
We could see a GREAT STORY IN THE MAKING !!!
GOOD LUCK AND TRADE OUT AT THE TOP.

Small-Cap Review

We want to congratulate all of our members who read our Trading Alert
on AXCP last time when we issued a Trading alert and saw 200%
in 3 days of trading.

On Monday we are issuingi a Trading Alert again on ALLIXON INTL CORP (AXCP)
at $3.35, we feel this is a Strong Buy at this price level
and say you should be putting this on your radar watch
for Monday September 26.

We think the fun is just beginning with this stock.
It has been showing a steady move up on increasing volume.
The chart on AXCP is a thing of beauty as it shows
what we mentioned earlier slow and steady upward movement.
It appears to us that the stock is in an accumulation phase
and might be ready for a big pop to new highs.
That would be well over a 300% gain from these levels.
So if you haven't done your DD yet, you better hurry
because it appears that the huge move is about to start.

Symbol: AXCP
Price: $3.35

Buy: Strong
Expectations: 200-400%

Allixon International Corporation Hires Investor Relations Firm
Select Equities Consultants
Saturday September 24, 12:15 pm ET

SEOUL, Korea, Sept. 24, 2005 (PRIMEZONE) - Allixon International Corporation

(Other OTC:AXCP.PK - News) is pleased to announce that it has hired
the Investor Relations firm Select Equities Consultants headed
by Mr. Robert Collard, CEO, to provide Investor Relations services
to its shareholders and other key stakeholders.

ADVERTISEMENT

Select Equities will, amongst other things, further develop
and maintain Allixon's current database, which will allow Allixon
to effectively monitor and communicate with present and potential investors,

fund managers, financial analysts, investment bankers, stock brokers,
financial media and other interested parties. Select Equities will also
receive,
review and screen investor inquiries on behalf of the company and reply to
and/or forward such inquiries to appropriate managers of Allixon.
In general, Select Equities will assist and promote the dissemination
of information regarding Allixon to potential investors and other
interested parties in the investment community; and to advise on
advertising,
trade shows, conferences and the like. It is not proposed that Select
Equities
will enter into any market making arrangements on behalf of Allixon.

Under the terms of the agreement with Allixon, Select Equities will continue

for 90 days with a renewal option unless terminated for just cause
or if either party gives the other party one month written notice.
In consideration of Select Equities performing the investor relations
services,
Allixon has agreed to pay him $15,000 per month. Select Equities does not
own
any securities of Allixon but may acquire securities in the future.

THIS NEWS RELEASE DOES NOT CONSTITUTE ANY OFFER OF ANY SECURITIES FOR SALE.

About Select Equities Consultants

Select Equities is an Investor Relations and Advertising firm based
in Heathrow, Florida. The firm primarily disseminates information about
small
to medium sized Publicly Traded companies. Select Equities services
also includes company Press Releases, Investor Conferences, company
sponsored
Broker Seminars, and Financial Publications.

About Allixon International Corporation

Allixon is a leading provider of RFID Middleware and Mobile Internet
solution
for device computing. Allixon combines its products, expertise, partnerships

and integration capability into solutions for a wide range
of device computing applications, including RFID Middleware and m-banking
solution.
Allixon's products based on ubiquitous technologies direct companies looking

to tap into the wealth of data captured by networked devices such
as RFID readers or handhelds to extend the quality of information
to any device where they want. The company is headquartered in Soeul, Korea
-
1564-1, Seojin Bldg 3FL., Seocho3-Dong, Seocho-Gu, Seoul, Korea 137-868.

****WATCH****WATCH****WATCH****WATCH****WATCH****WATCH****WATCH****
Few Allixon Partners: IBM, MICROSOFT, SUN, KOREA FIRST BANK, SAMSUNG,
FUJITSU...

Dermisonics: breaking ground in drug technology

 

Dermisonics (OTCBB: DMSI) Ultrasonic patch or injection? A new drug delivery technology that gets “under your skin”… Rating (12 month):        Speculative buy   Last rating change:      First evaluation Target price:      USD 4.40 Price (16.09.2005, 11:22am ET):      USD 0.825 High/Low 250 days:      USD 1.80 / 0.57 Next analysis:      Update   Dermisonics, Inc. (DMSI.OB) Ultrasonic patch or injection? A new drug delivery technology that gets “under your skin”… Dermisonics (DMSI.OB) : In a departure from heretofore unsuccessful “needle-free injections” attempted in the past, Dermisonic’s technology is based on the use of ultrasonic impulses delivered to and through the drug patch that enlarge pores in the skin to the extent that the active ingredient of the pharmaceutical reaches the bloodstream directly, bypassing the potentially harmful effects of the human digestive system. A Revolutionary Discovery for Drug Delivery. By opening the targeted pores and kinetically motivating the drug molecules with the ultrasonic signal, larger drug profiles than ever considered before have been made to dance their way into patients systems – more than 175 drug therapy compounds qualify for this technique, offering painless solutions for the chronically ill. Dermisonics could therefore really hold the key to an entire range of new possibilities in transdermal active ingredient applications. Dermisonics’ fundamental work is complete: A US patent covering the core technology has been issued, and 11 others have already been applied for to include further specifications. Studies in human beings with a standard insulin preparation – until now on healthy volunteers – successfully proved high dosing levels. In addition to circles of medical experts, such as the well-known German diabetes researcher Professor Heinemann from Neuss, leading pharmaceutical companies have also begun to intensively study this new technology. Planning of the first pre-clinical testing as a prelude to a human clinical trial with diabetic patients has just been announced (see the company’s press release of August 1, 2005), and will take place in a cooperative effort with two insulin manufacturers. When is the right time for you to buy this stock? We have been following the development of Dermisonics for nearly one year, but only now does it seem to us that right moment has come to get involved: The basic technology has been secured and the expansion into the cosmeceuticals sector, in our opinion, considerably enhances the company’s prospects. Also the company’s stock – at least in the USA – has shown clear signs of an upswing in turnover in recent weeks, which also reduces risk. Moreover, while Dermisonics is still officially a company in the research and development phase, its marketing strategies are already taking shape and dynamic development is anticipated in the coming weeks. The management is already estimating the probability of success at 80-85%. We are a bit more careful and calculate the chances of success at 25%, which can be considered standard for phase 1b of the clinical trials of a medical technical device. Nevertheless, even on this basis, a significant under-valuation is indicated for Dermisonics with a price potential of over 300%. The table below clearly shows the earnings value per share that can be anticipated for the U-Strip technology depending on the individual phases of the clinical trials and the FDA approval process:     Claudia Meissner on: A new drug delivery technology that gets “under your skin…”     Financial Analyst: Claudia Meissner, Biologist   COMPANY: Dermisonics Inc. Stock Symbol: OTCBB: DMSI Basic Information :       The stock markets may also have inaccurate cost concepts colored by the development of medicines. No more than USD 200,000 will be required for the new series of tests. And for the subsequent phase 2 for final market approval, a budget of USD 8-9 million has been set for the 6-week long test with 250 patients at five different locations. These low costs for market approval will certainly not be a hindrance with the major insulin manufacturers jockeying for position to conclude licensing agreements with Dermisonics. What are the prospects for success for the U-Strip technology and what do they mean for the value of Dermisonics? As can be seen, Sanofi Aventis is attempting to establish its place in the U.S. insulin market, while the old bull Eli Lilly must defend its turf. This is justification enough for one of the two – or even a niche supplier, to help themselves to a larger piece of the pie through an association with Dermisonics. And this is no mere pie in the sky, as is indicated by the fact that Dermisonics is carrying out the planning of the now upcoming second phase of the human pilot trial - the human trial protocol – in close cooperation with multiple manufacturers. In 4-5 weeks we will know for sure. By then, the U-Strip technology will have been successively tested on diabetic patients at the Dr. Rex Kessler Research Institute under the supervision of the State Universityof Pennsylvania.  Dermisonics hopes that they will be able to prove at least the equality of its technology with the Minimed pump. If the dosing results among the diabetes are even nearly as successful as those among the test trial participants, then this data should place Dermisonics in a very promising bargaining position in terms of licensing agreements with the insulin manufacturers. What is diabetes and what benefit does the U-Strip technology from Dermisonics offer patients? While diabetes is only the fifth most common cause of death in the USA, due to the duration of its treatment, it is the most expensive chronic disease there is, currently suffered by around 16 million Americans. This figure is increasing by nearly five percent each year. For diabetics, the body is no longer capable of – or insufficiently capable of – maintaining its blood sugar level (glucose). This is achieved through the natural hormone insulin, which is produced in the pancreas.

In extreme cases, untreated diabetes can lead to lethal shock, and even with consistent treatment, life expectancy decreases by an average of 15 years. In around 10 percent of those afflicted the pancreas is unable to produce any insulin at all from birth (juvenile diabetes or diabetes type 1). However, the vast majority of diabetics experience malfunctioning insulin production later in life (adult diabetes or diabetes type 2), primarily as a result of improper nutrition or lack of exercise, making it a typical civilization illness. Approximately 25% of this group must regularly inject insulin, while most can rectify the problem with a therapy consisting of a diet regime and pills to sink the blood sugar level. Ultimately, however, it nearly always leads to the administration of insulin. Health professionals agree: It would be beneficial to many patients to begin insulin applications earlier, however, most naturally abhor injections and postpone taking this step for as long as possible. An alternative supply option without injections would thus be more than desirable and could establish an additional market beyond the 25% named. Everyone is currently talking about the new insulin drug which can be inhaled as a spray. This does not represent competition for Dermisonics because the spray solution is only intended to control blood sugar spikes after meals. There are two specific applications to consider for which the various manufacturers offer different insulin preparations: One is for maintaining a constant blood sugar level throughout the day, while the other is for handling blood sugar spikes after meals. Dermisonics is focusing on the long-term supply market.   A high degree of mobility is already offered by insulin pumps, which like the U-Strip is carried on the body, however, which is connected through a canula. Nevertheless, nearly 5%, or around 200,000 diabetics, have decided for this solution. The leading manufacturer (approx. 70% market share) is Medtronic, Inc. which with its Minimed insulin pumps has already written an extraordinary success story and in just a few years was able to generate turnover amounting to over USD 1.6 billion in the neurology sector. The market that Dermisonics intends to enter thus already exists and could grow even larger, since what is being introduced is a painless solution. In our analysis, we only assumed that the company will manage to also win over 200,000 diabetics to its solution over a period of 5 years, or no more than those currently using insulin pumps. Skincare Applicator (U-Wand) a new application with great potential. If it is possible to use ultrasound to transport active ingredients through the skin to the bloodstream, then it should not be at all difficult to have such ingredients end up in the lower layers of the skin. This slight alteration of the Dermisonic’s concept could prove to be extremely effective, because it opens the door to an entirely new range of applicatory possibilities, cosmeceuticals, which are a cross between pharmaceutical and cosmetic products. The best known example is Botox, a nerve toxin which when injected in low doses just below the skin paralyzes facial nerves and thus makes wrinkles disappear for several months. Another example is Collagen, a structural protein of the connective tissue, which has been used for years in creams or is even injected to fortify the skin and thereby has a smoothing effect. The desire for eternal youth and the increasing societal acceptance of corresponding medical interventions and treatments have led to entirely new growth markets for the cosmetics industry. Although Botox was first approved by the FDA for cosmetic purposes in 2002, it already generates annual turnover for its manufacturer Allergan, Inc. amounting to USD 716 million, and increasing. The patent application for this SkinCare Applicator, originally called U-Wand, or ultrasound wand, has already been submitted, and there is no lack of creams which could provide more lasting effects with the SkinCare Applicator. We are convinced that Dermisonics will soon be able to announce the first product partnerships in this sector. By then, at the very latest, the first economic evaluation of the ultrasound specialist’s second main pillar should be possible. One aspect to be considered, particularly from an investor's point of view, is that creams and similar substances do not need to be approved by the FDA; not even internal tolerance tests are required to place such products on store shelves. As a cosmetic product, this should also apply to the SkinCare Applicator, as along as it can be ensured that penetration of the substance into the bloodstream can be avoided through the frequency and duration of the ultrasound application. Thus, the "residual FDA risk" can be excluded in our opinion in contrast to insulin supply application, while the market and price potential seems to actually be at least as large. Just go to the Dermisonics' website: for more exciting info. For more information fo to: and view the featured video interviews! Buy Dermisonics today at the market price. Since this is a highly speculative trade, though, please do limit your position here to a small percentage of your overall portfolio.

IMPORTANT NOTICE AND DISCLAIMER: This featured company sponsored advertising issue of Bull-and-Bear is presented by DD Investment, the private owner and publisher of Bull-and-Bear. Bull-and-Bear and DD Investment shall hereinafter be collectively referred to as Bull-and-Bear. Bull-and-Bear does not purport to provide an analysis of any company's financial position, operations or prospects. This document is not to be construed as a recommendation by Bull-and-Bear or as an offer to buy or sell any security. Bull-and-Bear presents information in this report believed to be reliable, but its accuracy cannot be guaranteed by Bull-and-Bear. Dermisoncs' financial position and all information relating to the operations of Dermisonics should be verified with the company. Investing in securities is speculative and carries risk. You can lose all or part of your investment. It is recommended that any investment in any security should be made only after consulting with your investment advisor and only after reviewing the prospectus and/or financial statements of the target company. Information about publicly listed companies and other investor resources can be found at the Securities & Exchange Commission website http://www.sec.gov. Bull-and-Bear.tv's objective is to give the investor the necessary knowledge and information with which to make rational and profitable investment decisions. Neither Bull-and-Bear.tv nor the featured analyst received monetary compensation with respect to the writing of this special report. Dermisonics, the company featured in this issue, appears as paid advertising, subsidized by BX Inc., a non-controlling shareholder of Dermisonics, to provide public and investor awareness for Dermisonics. Neither BX Inc., its employees and affiliates nor Bull-and-Bear.tv are investment advisors and are not affiliated with each other, either directly or indirectly. Many states have established rules requiring the approval of a security by a state security administrator. Check with www.nasaa.org or call your state security administrator to determine whether a particular security is licensed for sale in your state. Many companies have information filed with state securities regulators and many will supply investors with additional information upon request. The information contained herein contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934, including statements regarding expected continual growth of the featured company. In accordance with safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the statements contained herein that look forward in time, which include other than historical information, involve risks and uncertainties that may affect actual results of operations. Factors that could cause actual results to differ materially include, but are not limited to, adverse economic conditions, intense competition, lack of meaningful research results, inadequate capital, termination of contracts or agreements, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, and other specific risks detailed in Dermisonics' filings with the Securities and Exchange Commission on Form 10-KSB and 10-QSB. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance may be forward-looking statements. Forward-looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements may be identified through the use of words such as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should or might occur.

 

 

Investors Micro-cap Profile for You

We want to congratulate all of our members
who read our Trading Alert on AXCP.
We gave it too you at $2.75 and now it is at $5.75
and looking better then ever.

On Wednesday we are issuing a Trading Alert on: m-Wise, Inc.
(OTC BB:MWIS.OB)

But we think the fun is just beginning with this one.
It has been showing a steady move up on increasing volume.
The chart on MWIS is a thing of beauty as it shows
what we mentioned earlier slow and steady upward movement.
It appears to us that the stock is in an accumulation phase
and might be ready for a big pop to new highs.
That could well be over a 300% gain from these levels.
So if you haven't done your DD yet, you better hurry
because it appears that the huge move is about to start.

Symbol: MWIS
Price: .165

Buy: Strong
Expectations: 300-500%

NEWS RELEASE:
m-Wise's MOMA Platform Selected By The Ring Ring Company
as Its Main Technology and Application Platform
WILMINGTON, Del., 2005 (PRIMEZONE) -- m-Wise, Inc.
(OTC BB:MWIS.OB - News), a leading technology provider
of mobile content solutions for operators, ASPs and content providers,
today announced the launch of its MOMA Platform with Belgium-based,
The Ring Ring Company, the leading Wireless Application Service Provider.
m-Wise will supply Ring Ring with its MOMA Service Delivery Platform (SDP).
MOMA will become Ring Ring's main technology and application platform.

Ring Ring is one of the first providers of premium SMS and MMS services
in Belgium and a specialist in IVR and mobile services.
Ring Ring has licensed m-Wise's MOMA SDP to run its existing applications,
while generating and developing new ones through the m-Wise technology.
Installed locally, the MOMA SDP will allow Ring Ring to quickly
and efficiently implement the new value-added mobile services
to the Belgian market in the upcoming months.
As a result of its direct connections with Belgian-based
telecommunications operators, its client portfolio and its market knowledge,

Ring Ring is currently a top-three player in the Belgian mobile
communications market. Utilizing the MOMA SDP, Ring Ring can run services
with ease, including SMS and MMS and the supply of information
and entertainment services, Location Based Services
and other interactive services.

"We are delighted to launch the MOMA SDP as our main technology
and application platform. We were looking for a total solution
and chose MOMA because it offered a robust and reliable platform
that can expand with our needs, while allowing us to customize it
to our requirements and streamline our technology," said Walter Mortelmans,
chief executive officer of The Ring Ring Company.

"Our MOMA Service Delivery Platform appeals to the large-scale WASPs
for companies such as The Ring Ring Company, that require a robust,
reliable system to develop and support their services,"
said m-Wise's Vice President of Sales and Marketing, Zach Sivan.
"We are pleased that Ring Ring will be utilizing our platform
to roll out their products in Belgium."

Now comprising of more than 1,000 value-added services
and applications launched through more than 50 European, Latin American
and Asian networks, m-Wise provides the industry's most robust
and critical Service Delivery Platform for mobile operators,
wireless ASP's and large content and media providers.
The MOMA SDP increases data traffic and premium revenues
and considerably minimizes capital, commercial, training
and technical requirements for the management and control
of value-added-services by providing a unified solution
for clients' respective VAS departments such as IT, marketing,
customer care and billing departments.

We have seen people double and triple there money,
we ask you too put MWIS on your radar and WATCH this trade
on Wednesday September 21, 2005

Disclaimer:
Information within this email contains "forward looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21B of the Securities Exchange Act of 1934. Any statements
that express or involve discussions with respect to predictions, goals,
expectations, beliefs, plans, projections, objectives, assumptions
or future events or performance are not statements of historical fact
and may be "forward looking statements."

Forward looking statements are based on expectations, estimates and
projections at the time the statements are made that involve a number
of risks and uncertainties which could cause actual results or events
to differ materially from those presently anticipated. Forward looking
statements in this action may be identified through the use of words
such as: "projects", "foresee", "expects", "estimates," "believes,"
"understands" "will", "anticipates," or that by statements indicating
certain actions "may," "could," or "might" occur. All information
provided within this email pertaining to investing, stocks,securities
must be understood as information provided and not investment advice.
Emerging Equity Alert advises all readers and subscribers to seek
advice from a registered professional securities representative before
deciding to trade in stocks featured within this email. None of the
material within this report shall be construed as any kind of
investment advice.

In compliance with Section 17(b), we disclose the holding of shares
of axcp prior to the publication of this report. Be aware of an inherent
conflict of interest resulting from such holdings due to our intent
to profit from the liquidation of these shares. Shares may be sold at
any time, even after positive statements have been made regarding
the above company.

Spec-Money stock

Symbol: CWTD
Price: $1.95
Recommendation: Great

We see this company doing Great things and we feel you should put
this on your RADAR ALERT for Tuesday September 20, 2005

***NEWS***NEWS***NEWS***NEWS***NEWS***NEWS***NEWS***
China World Trade Corporation Announces Record
Second Quarter 2005 Revenue Growth
Second Quarter 2005 Revenues Up 405% Year over Year

TIANHE, Guangzhou, China, Sept. /Xinhua-PRNewswire/ -
China World Trade Corporation (China WTC) (OTC Bulletin Board: CWTD - News)
announced today record second quarter revenue growth and net profit
for the quarter ended June 30, 2005.

***WATCH THIS ONE September 20, AS WE KNOW MANY OF YOU LIKE MOMENTUM***

Timing is everything!!!!!
Profits of 300-400 % EXPECTED

Good day to all broker's, Day Trader's and Investor's World stock report
has become famous with some great stock picks in the otc, small cap
market's!!! Here at World Stock Report we work on what we here
from the street. Rumor's circulating and keeping the focus on the company's
news. We pick our companies based on there growth potential. We focus on
stocks that have great potential to move up in price!!! While giving
you liquitity.

HUGE PR campaign expected this week so grab as much as you can.

****************PRESS RELEASE****************PRESS RELEASE****************
China World Trade Corporation Reports Record Earnings in the Second Quarter
2005

China World Trade Corporation (CWTC) has established its business
in three distinct areas: the club and business centers throughout major
cities
in China, business travel-related services, and business value-added
services.
The Club and Business Center Division is devoted to the building
of the World Trade brand throughout China via the opening and operating
of business clubs in China's major, positioning the CWTC to act
as a platform to facilitate trade between China and the world markets.
The acquisition of CEO Clubs China Limited ("CEO Clubs") in May 2004
further complements CWTC's offerings by targeting high-level corporate
executives
from premier companies. The Business Traveling Services Division, New
Generation,
provides CWTC access to the rapidly growing travel-related industry.
New Generation is a pioneer and market leader in the travel agency business
through
its strong network of ticketing sales operations throughout Southern China.
The Business Value-Added Services Division focuses on value-added services
of credit cards, merchant-related business services, as well
as consultancy services to CWTC members and clients.
Guangdong World Trade Link Information Services Limited ("WTC Link"),
a subsidiary of CWTC, manages the Company's co-branded credit card project
and is an active provider of CRM solutions and services in China.

THIS COMPANY IS DOING INCREDIBLE THINGS. THAY HAVE CASH AND HAVE MADE
GREAT STRATEGIC AQUISITIONS. CURRENT PRICE $1.95. WORD IS THAT THE STOCK
is a steal at this price.. THEY HAVE DROPPED BIG NEW'S IN THE PAST.
WHO'S TO SAY THEY DON'T HAVE ANOTHER BIG ONE.

We issued a Investors Alert For Monday September 19, and look what happened:

AXCP: UP 0.50 (10.53%) at close
CDGT: UP 0.40 (26.49%) at close

Do this often enough, and your portfolio can double, even TRIPLE in value.

Will this stock be a SuperNova?

Investor Alert - WE HAVE A RUNNER - STOCK IS UP (98%) in 3 Trading Days !!!

SYMBOL: AXCP
CURRENT PRICE: $4.75
7 DAY TARGET: $10.00

We Told Sep 13 at 2.40 to WATCH and now its $4.75 and
we think it goes to $10.00 (!!!) on expected news this week...

===
About Allixon International Corporation

Allixon is a leading provider of RFID Middleware and Mobile Internet
solutions
for device computing. Allixon combines its products, expertise, partnerships
and integration capability into solutions for a wide range
of device computing applications, including RFID Middleware and m-banking
solution.
Allixon's products based on ubiquitous technologies direct companies looking
to tap into the wealth of data captured by networked devices such
as RFID readers or handhelds to extend the quality of information
to any device where they want.
===

Big news expected.
This stock will explode!
Do not wait until it is too late!!!

stockmarket Smallcap Profile

EXPLOSIVE PICK FOR OUR MEMBERS.
TRADING ALERT!

Date: 16 Sep 2005
Company: Allixon International Corporation
Trading Symbol: AXCP.PK
Current Price: 4.25
Projection 5 to 7 Days: 6.50 - 8.50
Projection 8 to 12 Days: 9.00 - 12.00

-----
Press Release Source: Allixon International Inc.

Allixon Awarded Contract to Develop the RFID-Based Access Control System
and Strategic Materials Management System with the Ministry of Unification
Friday September 16, 6:00 am ET

SEOCHO-KU, SEOUL, Korea, Sept. 16, 2005 (PRIMEZONE) -
Allixon International Corporation (Other OTC:AXCP.PK - News) is pleased
to announce that it was selected by the Ministry of Information
and Communication (MIC) to complete an RFID-based Access Control System
and Strategic Materials Management System for the MIC's RFID business.
In the spring of 2005, the National Computerization Agency (NCA) published
RFP's for 5 projects to be completed by the following spring 2006.

About Allixon International Corporation

Allixon is a leading provider of RFID Middleware and Mobile Internet
solutions
for device computing. Allixon combines its products, expertise, partnerships

and integration capability into solutions for a wide range
of device computing applications, including RFID Middleware and m-banking
solution.
Allixon's products based on ubiquitous technologies direct companies looking

to tap into the wealth of data captured by networked devices such
as RFID readers or handhelds to extend the quality of information
to any device where they want.
-----

GET AXCP FIRST THING FRIDAY, THIS IS GOING TO EXPLODE IN THE NEXT 2-5 DAYS.

Stock Alert

Did you turn a 4,000% gain on your investment in one month??

If you bought Gulf BioMedical Corporation (OTC PK: GBIC) you

would have realized a 4,000% GAIN in 30 days GBIC surged from

$.05 cents to $4.00 on heavy volume.

   Ascentia BioMedical Corporation (OTC PK: ASCE) is our latest

Hot BioMedical Stock Pick!!! Ascentia BioMedical Corporation is

a microcap company which recently went public and has announced

an Anti-Cancer Compound. This company is a leading edge

research and developer of highly promising pharmaceutical

families that have already undergone significant discovery,

exploration and testing. Ascentia BioMedical is publicly traded

under the ticker symbol ASCE.

   ASCE is priced at $0.95 cents. Look for large volume

increases, followed by a sharp rise in share price. Don't Miss

Out on the next BIG move.

Current price:  $0.95 cents per share

Symbol:

Current Price

        ASCE

95 cents

6 Month Price Target                    $2.50

For More Information visit: http://www.ascentiabiomedical.com

   Ascentia BioMedical Corporation has fundamental investor

facts speculative investors should take notice of:

   * Anti-Cancer Compound: Ascentia announces option agreement

with University of Washington for Anti-Cancer Compound.

Compound has already shown repeated efficacy in blocking tumors

in a relevant, pre-clinic model of breast cancer.

   * Promising Pharmaceutical Drugs: Ascentia's core business

is to develop highly promising pharmaceutical families that

have already undergone significant discovery, exploration and

testing.

   * Price Target: Ascentia's stock is tightly held with a

small float. This share structure allows for a strong surge in

share price. 6 Month Price Target $2.50.

The Company:

   Ascentia BioMedical Corporation (ASCE) is developing and

commercializing new pharmaceutical and biomedical products for

application in a number of areas, including treatment for

asthma, arthritis, psoriasis and cancer. Initially, a majority

of these products will be secured through direct purchase or

through licensing. Initially, a majority of these products will

be secured through direct purchase or through licensing.

Ascentia is focused on therapies for cancer and diseases of

inflammation.

Company Highlights:

   ASCE Announces Option Agreement with University of

Washington for Anti-Cancer Compound: Compound already shown

repeated efficacy in blocking tumors in a relevant,

pre-clinical model of breast cancer.

   ASCE Begins Trading on OTC Pink Sheets: Ascentia BioMedical

Corporation, a leading research and developer of efficacious

pharmaceuticals, compounds and other products, announced its

common stock has begun trading under the ticker symbol ASCE.

Dr. James Clagett, President and CEO of Ascentia stated "we are

pleased to have begun trading on the Pink Sheets. It is the

first step of our goal of being listed on a national exchange.

We are excited about the prospects for our research and

products. With a growing balance sheet, an experienced

management team and a "Who's Whoâ€' for a Scientific Advisory

Board, we are well positioned for future growth.

        REASONS TO BUY THIS STOCK TODAY.

   1.) Promising Pharmaceutical Drugs: Ascentia's core business

is to develop highly promising pharmaceutical families that

have already undergone significant discovery, exploration and

testing.

   2.) Anti-Cancer Compound: Ascentia announces option

agreement with University of Washington for Anti-Cancer

Compound. Compound has already shown repeated efficacy in

blocking tumors in a relevant, pre-clinic model of breast

cancer.

   3.) Revenues: Ascentia is currently generating revenues from

contract research for third parties.

   4.) Long-term Revenues: Ascentia has a number of

opportunities to "in-license" proprietary pharmaceutical

products that will provide long-term revenue streams with

upfront milestone payments.

   5.) Advisory Board: Board comprises "Who's Who of

Scientists.

   6.) Price Target: Ascentia's stock is tightly held with a

small float. This share structure allows for a strong surge in

share price. 6 Month Price Target $2.50.

   Investment Opinion: Take advantage of current trading

levels. This is a ground floor opportunity you can't afford to

miss. At current price levels, a little bit of movement will go

a long way.

   Look for heavy volume and significant price increases in the

short term. The price of ASCE is currently trading at $0.95.

This is an inexpensive stock by anyone's standards. Don't Miss

Out.

Current Price: 0.95 cents

change subscription , please email

ocalamailman@ocalasuccess.info

with subscription in subject line

3645 ne18th Court

Ocala,Fl 34479

A Special Alert to Investors

A Special Alert to Investors

Looking for a company with some good news? Here's one!
UP WE ARE LOOKING FOR A HUGH THURSDAY !

Date: 15.09.2005
Company Name: m-Wise, Inc.
Trading Symbol: MWIS.OB
Opening Price: $.13
10 Day Target: $.60

THIS IS THE ONE THAT COULD MAKE YOU 300-500% PROFIT!!!

---
m-Wise, Inc. (OTC BB:MWIS.OB - News), a leading technology provider
of mobile content solutions for operators, ASPs and content providers,
today announced the launch of its MOMA Platform with Belgium-based,
The Ring Ring Company, the leading Wireless Application Service Provider.
m-Wise will supply Ring Ring with its MOMA Service Delivery Platform (SDP).
MOMA will become Ring Ring's main technology and application platform.

Ring Ring is one of the first providers of premium SMS and MMS services
in Belgium and a specialist in IVR and mobile services. Ring Ring has
licensed
m-Wise's MOMA SDP to run its existing applications, while generating
and developing new ones through the m-Wise technology. Installed locally,
the MOMA SDP will allow Ring Ring to quickly and efficiently implement
the new value-added mobile services to the Belgian market in the upcoming
months.
As a result of its direct connections with Belgian-based telecommunications
operators,
its client portfolio and its market knowledge, Ring Ring is currently
a top-three player in the Belgian mobile communications market.
Utilizing the MOMA SDP, Ring Ring can run services with ease,
including SMS and MMS and the supply of information and entertainment
services,
Location Based Services and other interactive services.
---

GET IN NOW!!! You know the old saying, buy the rumor and sell on the news.
Once the news is out it is time to get ready for next rally...

A $1,000 dollar investment could yield a $5,000 dollar profit in
just one trade if you trade out at the top. MWIS should be one of the most
profitable stocks to trade this year. In this range the stock has
potentialto move in either direction in bigs wings. This means
you should be able to buy at the lows and sell at the highs for months to
come.

We could see a GREAT STORY IN THE MAKING FOR MWIS.

!!!GOOD LUCK AND TRADE OUT AT THE TOP!!!!